SiBone (NASDAQ:SIBN – Free Report) had its target price hoisted by UBS Group from $25.00 to $26.00 in a report released on Tuesday,Benzinga reports. The firm currently has a buy rating on the stock.
Other equities analysts also recently issued research reports about the company. Citigroup reiterated a “market outperform” rating on shares of SiBone in a report on Tuesday. Weiss Ratings upgraded shares of SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 20th. TD Cowen upped their price objective on shares of SiBone from $20.00 to $23.00 and gave the stock a “buy” rating in a report on Tuesday. Truist Financial raised their target price on shares of SiBone from $23.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, October 14th. Finally, Needham & Company LLC dropped their target price on shares of SiBone from $27.00 to $26.00 and set a “buy” rating on the stock in a report on Tuesday. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $25.00.
Check Out Our Latest Report on SiBone
SiBone Price Performance
Shares of SIBN opened at $24.27 on Tuesday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 7.55 and a current ratio of 7.58. The firm has a market cap of $1.09 billion, a PE ratio of -78.29 and a beta of 0.64. The firm’s 50 day moving average price is $19.71 and its 200 day moving average price is $16.56. SiBone has a twelve month low of $11.48 and a twelve month high of $25.92.
SiBone (NASDAQ:SIBN – Get Free Report) last released its quarterly earnings results on Monday, November 2nd. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.05. The business had revenue of $55.70 million for the quarter, compared to the consensus estimate of $55.31 million. SiBone had a negative net margin of 6.20% and a negative return on equity of 7.57%. As a group, research analysts expect that SiBone will post -0.34 EPS for the current fiscal year.
Insider Activity at SiBone
In other SiBone news, CEO Laura Francis sold 51,884 shares of the firm’s stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $19.46, for a total value of $1,009,662.64. Following the sale, the chief executive officer directly owned 321,386 shares in the company, valued at $6,254,171.56. This trade represents a 13.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Jeffrey W. Dunn sold 20,000 shares of the firm’s stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $18.47, for a total transaction of $369,400.00. Following the completion of the sale, the director owned 16,057 shares in the company, valued at $296,572.79. This represents a 55.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 258,371 shares of company stock valued at $5,156,716 in the last 90 days. 4.00% of the stock is owned by company insiders.
Institutional Investors Weigh In On SiBone
Institutional investors have recently added to or reduced their stakes in the company. Versant Capital Management Inc grew its position in SiBone by 102.9% in the second quarter. Versant Capital Management Inc now owns 1,749 shares of the company’s stock valued at $29,000 after acquiring an additional 887 shares during the period. State of Wyoming raised its stake in SiBone by 70.8% during the first quarter. State of Wyoming now owns 10,832 shares of the company’s stock worth $137,000 after acquiring an additional 4,490 shares in the last quarter. Inceptionr LLC bought a new position in shares of SiBone during the first quarter valued at $156,000. ADAR1 Capital Management LLC bought a new position in shares of SiBone during the first quarter valued at $159,000. Finally, Elevation Point Wealth Partners LLC bought a new position in shares of SiBone during the first quarter valued at $204,000. 98.11% of the stock is owned by institutional investors and hedge funds.
About SiBone
SI-BONE, Inc (NASDAQ: SIBN) is a medical device company focused on diagnosing and treating disorders of the sacroiliac joint, which connects the spine to the pelvis. The company develops minimally invasive surgical solutions intended to stabilize the sacroiliac joint and address sacroiliac joint dysfunction and related conditions.
Its product portfolio is centered on the iFuse Implant System, a family of triangular implants designed to be placed across the sacroiliac joint. SI-BONE also offers products such as iFuse-TORQ, a threaded implant system, and iFuse Bedrock Granite, which is designed for sacroiliac joint fusion and pelvic fixation as part of certain spinal procedures.
Featured Articles
- Five stocks we like better than SiBone
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for SiBone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SiBone and related companies with MarketBeat.com's FREE daily email newsletter.
